You are here

Development of a Multiplex Bioassay for Early Predictors of Multiple Organ Injury

Award Information
Agency: Department of Defense
Branch: Defense Health Agency
Contract: W81XWH-14-C-0155
Agency Tracking Number: H141-005-0073
Amount: $149,955.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: DHP14-005
Solicitation Number: 2014.1
Timeline
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): 2014-09-29
Award End Date (Contract End Date): 2015-05-14
Small Business Information
6201 East Oltorf St. Suite 400
Austin, TX 78741-7511
United States
DUNS: 100651798
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Steve Savoy
 VP Research and Development
 (512) 389-9990
 ssavoy@nanohmics.com
Business Contact
 Jonathan Stallings
Title: CPT
Phone: (301) 619-7628
Email: jonathan.d.stallings.mil@mail.mil
Research Institution
N/A
Abstract

Bioassays employed to assess the diverse range of toxicity associated with organ injury are time-consuming, costly and require multiple instruments and testing formats (i.e. fluorescence-based capture, ELISAs, PCR, etc.) to reach a diagnosis. These platforms are incapable of predicting the onset of irreversible organ (e.g. kidney, liver, heart and lung) tissue injury. If a single multiplexed screening bioassay could be fabricated to assess multiple, pre-clinical biomarkers that are predictive indicators of systemic toxicity, it would significantly reduce the complexity, expense and turnaround time associated rapid injury diagnostics. Research-based microarrays often involve many of the same labeling and amplification steps present in medical diagnostics. One barrier to transitioning microarray technology into multiplex medicinal diagnostics has been the limitations imposed by fluorescence/optical-based labeling and endpoint detection. To overcome these limitations, Nanohmics Inc., an early stage biotechnology and sensor development company, proposes the development of a multiplexed diagnostic platform based on direct electrical detection of pre-clinical and eventually clinical toxicity biomarkers for predictive tissue injury.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government